BMS-986120

BMS-986120 is a first-in-class, orally active, selective, and reversible small molecule antagonist of protease-activated receptor 4 (PAR4). It was developed as an antiplatelet agent with potent and selective inhibition of PAR4-mediated platelet activation and aggregation. The drug demonstrated robust antithrombotic activity in preclinical models with a potentially lower risk of bleeding compared to other antiplatelet agents. Clinical studies showed that BMS-986120 effectively inhibited PAR4-induced platelet aggregation in healthy volunteers without significantly affecting routine coagulation parameters or causing increased bleeding times. Despite promising early results, clinical development for thrombosis was discontinued after Phase 1/2 trials. The drug was originally developed by Bristol Myers Squibb[1][2][3][4][5][6][7].